These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19446719)

  • 61. Functional assays as prismatic views of drug activity: relevance to new drug discovery.
    Kenakin T
    J Recept Signal Transduct Res; 2008; 28(1-2):109-25. PubMed ID: 18437634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro screening for chemokine antagonists.
    Ribeiro S; Horuk R
    Expert Opin Drug Discov; 2009 Oct; 4(10):1017-34. PubMed ID: 23480395
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
    Xue CB; Chen L; Cao G; Zhang K; Wang A; Meloni D; Glenn J; Anand R; Xia M; Kong L; Huang T; Feng H; Zheng C; Li M; Galya L; Zhou J; Shin N; Baribaud F; Solomon K; Scherle P; Zhao B; Diamond S; Emm T; Keller D; Contel N; Yeleswaram S; Vaddi K; Hollis G; Newton R; Friedman S; Metcalf B
    ACS Med Chem Lett; 2010 Dec; 1(9):483-7. PubMed ID: 24900235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
    Zhang J; Wang J; Qian Z; Han Y
    J Thorac Oncol; 2019 May; 14(5):e102-e103. PubMed ID: 31027743
    [No Abstract]   [Full Text] [Related]  

  • 65. Cancer non-stem cells as a potent regulator of tumor microenvironment: a lesson from chronic myeloid leukemia.
    Mukaida N; Tanabe Y; Baba T
    Mol Biomed; 2021 Mar; 2(1):7. PubMed ID: 35006395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
    Ward ST; Li KK; Hepburn E; Weston CJ; Curbishley SM; Reynolds GM; Hejmadi RK; Bicknell R; Eksteen B; Ismail T; Rot A; Adams DH
    Br J Cancer; 2015 Jan; 112(2):319-28. PubMed ID: 25405854
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CCR5 as a treatment target in pulmonary arterial hypertension.
    Amsellem V; Lipskaia L; Abid S; Poupel L; Houssaini A; Quarck R; Marcos E; Mouraret N; Parpaleix A; Bobe R; Gary-Bobo G; Saker M; Dubois-Randé JL; Gladwin MT; Norris KA; Delcroix M; Combadière C; Adnot S
    Circulation; 2014 Sep; 130(11):880-891. PubMed ID: 24993099
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.
    Misner DL; Frantz C; Guo L; Gralinski MR; Senese PB; Ly J; Albassam M; Kolaja KL
    Br J Pharmacol; 2012 Apr; 165(8):2771-86. PubMed ID: 22029876
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Screening for GPCR Ligands Using Surface Plasmon Resonance.
    Navratilova I; Besnard J; Hopkins AL
    ACS Med Chem Lett; 2011 Jul; 2(7):549-554. PubMed ID: 21765967
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CCR5 pharmacology methodologies and associated applications.
    Mansfield R; Able S; Griffin P; Irvine B; James I; Macartney M; Miller K; Mills J; Napier C; Navratilova I; Perros M; Rickett G; Root H; van der Ryst E; Westby M; Dorr P
    Methods Enzymol; 2009; 460():17-55. PubMed ID: 19446719
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.